Related by context. All words. (Click for frequent words.) 71 MyoCell TM 64 prospective multicenter study 64 myogenic 63 thymosin beta 4 62 Anticalins ® 62 metaplasia 61 ventricular myocardium 61 receptor inhibitor 61 clinico pathological 61 Anticalins R 61 proteoglycan 60 STEEN Solution ™ 60 MyoCath R 60 Yondelis ® 60 tumorigenicity 60 microtubule inhibitor 60 myoblast 60 microRNA profiling 60 stem cell transplantations 60 BPS IC 60 metastatic neuroendocrine tumors 60 primary hyperparathyroidism 60 urothelial cancer 60 FDG PET imaging 60 bortezomib Velcade 60 p# biomarker 60 dosimetric 60 metabolomic profiles 59 intercellular signaling 59 Hematopoietic 59 multicentric 59 Squalamine 59 IgG1 antibodies 59 vinca alkaloid 59 BEXXAR Therapeutic Regimen 59 bronchoalveolar lavage BAL 59 clinicopathological 59 HER2 expression 59 haematologic 59 cytotoxicity assays 59 cardio renal 59 uricase 59 HepDirect prodrug 59 differential gene expression 59 hyperinsulinemic euglycemic clamp 59 pain palliation 59 PET tracers 59 chimeric monoclonal antibody 59 histological subtype 59 IntroductionThe 59 metabonomics 59 fusion enhancers 59 ESBA# 59 airway anatomy 59 prospective multicentre 59 electrophysiologic 59 AGHD 59 IMiDs ® compound 59 therapeutic aptamers 59 hESC derived cardiomyocytes 59 vitro cytotoxicity 58 genomic biomarker 58 intestinal mucosal 58 osteogenic 58 NOD mouse 58 hepatoma 58 mesenchymal stem cells MSCs 58 histone deacetylase inhibitor 58 LHRH receptor positive 58 aminotransferase 58 intra tumoral 58 lymphangiogenesis 58 nonvascular 58 efficacy evaluable 58 haematopoietic 58 pancreatic adenocarcinoma 58 antitumor effect 58 gastric carcinoma 58 haematopoietic stem cell 58 neurosensory 58 metastatic malignant 58 A1PI 58 intraobserver 58 physico chemical 58 CardioFit 58 topical formulations 58 vascular disrupting agents 58 renal tubular 58 proteomic analysis 58 hematopoietic cell 58 symptomatic paroxysmal AF 58 retrospective observational study 58 transplantation HSCT 58 immunoregulation 58 kallikrein 58 small molecule activators 57 synovial cells 57 YONDELIS 57 histologic subtype 57 riociguat 57 busulfan 57 submandibular gland 57 multicenter trials 57 periodontal tissues 57 mTOR inhibition 57 fosbretabulin 57 colorectal adenocarcinoma 57 Estrogen Receptor 57 Cloretazine 57 physicochemical 57 papillary renal cell carcinoma 57 Collategene 57 pretransplant 57 everolimus eluting stents 57 antiproliferative effects 57 Litx 57 Skeletal muscle 57 therapeutic monoclonal antibody 57 radioembolization 57 microvessel 57 PDE# inhibitors 57 FibroScan ® 57 oral mTOR inhibitor 57 paroxysmal nocturnal hemoglobinuria 57 humanized monoclonal 57 Histopathological 57 osteocalcin protein 57 CSF biomarkers 57 Meta analyzes 57 cleavable linker 57 effector function 57 recombinant interferon 57 noninfectious uveitis 57 autologous bone marrow 57 Kahalalide F 57 Lymph node 57 MTP inhibitor 57 Treg cell 57 kidney urologic 57 cytostatic 57 intradermal injection 57 Critical Limb Ischemia CLI 57 urothelial carcinoma 57 mononuclear cells 57 TÎ ² 4 57 TMEM 57 malignant pancreatic 57 erythropoietic 57 bone morphogenic protein 57 HeFH 57 liposomal formulation 57 SSc 57 endocrinologic 57 sGC 57 urolithiasis 57 allogenic 57 tissue oxygenation 57 clinical pharmacology studies 57 prostatic tissue 57 prostate cancer PCa 57 neurological manifestations 57 VerifyNow P#Y# 57 recurrent glioblastoma multiforme 56 osteoblastic 56 Helicobacter pylori eradication 56 antimetabolites 56 electroencephalographic 56 bladder carcinoma 56 adipose derived stem 56 GAMMAGARD 56 Anticalin ® 56 sonographically guided 56 metastatic lymph nodes 56 HNSCC 56 syngeneic 56 lymphoid cells 56 soluble CD# 56 Aviptadil 56 RT qPCR 56 chronic myocardial ischemia 56 Adult Stem Cell Therapy 56 biliary tract cancer 56 bronchogenic carcinoma 56 DiLA2 56 glycolytic pathway 56 mutated K ras 56 anti fibrotic 56 leiomyoma 56 doxorubicin HCl 56 transurethral 56 urothelial 56 thymidylate synthase TS 56 Trofex 56 Prospective Randomized 56 bleomycin 56 murine antibodies 56 SCIg 56 clonal expansion 56 hPTH #-# 56 Abeta peptide 56 endogenous ligands 56 SERCA2a 56 HSP# inhibitors 56 autologous tissue 56 PrevOnco ™ 56 perfusion MRI 56 Cardiotoxicity 56 juvenile chondrocytes 56 perioperative morbidity 56 rhGH 56 chemosensitivity 56 Microarray analysis 56 ImmuKnow assay 56 hypervascular tumors 56 Confocal microscopy 56 surgically resected 56 eTag assays 56 atherogenesis 56 prostate carcinoma 56 TBNA 56 thoracolumbar spine 56 MYLOTARG 56 PCWP 56 NTDDS 56 pharmacokinetic PK study 56 BrachySil TM 56 Aethlon Hemopurifier ® 56 Trandolapril 56 fibrotic disease 56 ImmuKnow 56 vivo potency 56 deacetylase inhibitors 56 CHAMPION PCI 56 pharmacodynamic markers 56 hypoperfusion 56 GRNCM1 56 peptibody 56 intracranial stenosis 56 urography 56 intracoronary 56 Peptidomics 56 #beta estradiol 56 β1 56 osteoconductive 56 renal allograft 56 transabdominal 56 FGFs 56 KRAS oncogene 56 immunotoxin 56 factor Xa inhibitor 56 Zavesca R 56 hyperphenylalaninemia HPA due 56 neoplastic cells 56 Tß4 56 risk reducing salpingo 56 hepatic arterial 56 IL# PE#QQR 56 percutaneous biopsy 56 BrachySil ™ 56 Androxal TM 56 authors hypothesized 56 ALA PDT 56 tumor excision 56 hepato 56 anti angiogenic agents 56 Leydig cells 56 anti CD3 antibody 56 histone deacetylase HDAC 56 multicenter clinical trials 56 transarterial 56 AtherOx 56 XIENCE V Everolimus Eluting 56 sCD# 56 MGd 56 Nitric oxide NO 56 Triapine R 56 EGFR tyrosine kinase inhibitors 56 metaanalysis 56 SGLT2 inhibitors 56 V Everolimus Eluting Coronary 56 pyrimidine 56 histopathological 56 haematological cancers 56 AFRS TM 56 nodal metastasis 56 lytic 56 coexpression 55 von Willebrand 55 Vascugel 55 Fas ligand 55 Leukine ® 55 MTT assay 55 Prolastin C 55 HIF 1a 55 leiomyomas 55 osteoid 55 transgenic mice expressing 55 miRview meso 55 HSCT 55 antitumor efficacy 55 Progenta TM 55 Cerashield TM 55 VEGF inhibitors 55 BioNumerik 55 NSCLC tumors 55 Parathyroid hormone 55 biologic therapeutics 55 multicentre study 55 atrioventricular 55 genomically 55 antiangiogenic agent 55 Ultrasonographic 55 VIBEX MTX 55 siRNAs targeting 55 acinar cells 55 PEGylated 55 targeted radiotherapeutic 55 ADVEXIN therapy 55 huN# DM1 55 mucosal immune 55 rFactor XIII 55 Vaxfectin R 55 Stereotactic radiosurgery 55 multiplex assay 55 myoblast therapy 55 bone marrow stromal cells 55 molecular biomarkers 55 sJIA 55 JAK2 inhibitor 55 NAGS deficiency 55 proteolytic 55 Cx# [002] 55 genes differentially expressed 55 Tr DNA 55 esterases 55 Solazed 55 Liprostin 55 radionuclide therapy 55 antiarrhythmic drug 55 poly ethylene glycol PEG 55 Lenocta 55 Primary endpoints 55 thetreatment 55 unconjugated 55 direct renin inhibition 55 CTEPH 55 MAGE A3 ASCI 55 murine mouse 55 Acute Decompensated Heart Failure 55 oncologic outcomes 55 OGG1 55 carcinoid tumors 55 CB2 receptor 55 femoral neck fracture 55 NFKBIA 55 S. maltophilia 55 Chrysalin 55 PTHrP 55 STEDESA 55 CFTR inhibitors 55 Thrombin 55 Vasogen Celacade 55 liposome formulation 55 mRNA sequences 55 Corgentin 55 stratifying patients 55 INTERCEPT platelets 55 immunocompetent 55 neuromuscular junction 55 clinically detectable 55 acetylcholinesterase AChE 55 CYT# potent vascular disrupting 55 mda 7 55 K ras mutations 55 tumor necrosis 55 cytokine receptors 55 somatostatin analog 55 neuropathologic 55 subthalamic nucleus STN 55 monoclonal anti 55 QuadraSphere 55 acinar 55 TTR amyloidosis 55 PCA3 gene 55 ZFP TF 55 pelvic lymphadenectomy 55 cardiac perfusion 55 proteins peptides 55 allogeneic hematopoietic stem cell 55 beta globin gene 55 prostacyclins 55 chemoresistant 55 poloxamer 55 serum leptin 55 gene locus 55 VATS lobectomy 55 bone morphogenetic proteins BMPs 55 osteoinductive 55 somatostatin receptors 55 MDCK 55 Electroencephalography 55 subcutaneous immunoglobulin 55 PROCHYMAL 55 carotid artery stenting CAS 55 IL 1ß 55 #F FDG PET 55 bladder augmentation 55 SIR Spheres 55 ischemic mitral regurgitation 55 SSc patients 55 concurrent chemoradiation 55 carotid artery stenting 55 colon carcinoma 55 pro angiogenic 55 Hepatocellular Carcinoma HCC 55 peptide conjugated 55 Zevalin consolidation 55 immune modulating 55 ganaxolone 55 cardiac troponin 55 photocoagulation 55 sargramostim 55 genetic loci 55 prospective nonrandomized 55 TMPRSS2 ERG fusion 55 Clusterin 55 malignant ascites 55 mITT population 55 rxRNA 55 IPAH 55 mesenchymal stem cell 55 targeted antifolate 55 HIV HCV coinfected 55 AA Amyloidosis 55 DIABECELL 55 choroidal neovascularization 55 monomeric 55 neoplastic transformation 55 viscoelastic properties 55 EP #R 55 differentiate squamous 55 tumor specific antigen 55 cTnI 55 anti CD# antibodies 55 capsular polysaccharide 55 phenotypic expression 55 radiochemotherapy 55 Tasigna prolongs 55 gastrointestinal stromal tumors GISTs 55 neovascular 55 galectin 3 55 ENMD # 55 DNA methylation patterns 55 percutaneous vertebroplasty 55 Systemic Delivery 55 Proteostasis Network 55 JAK inhibitors 55 PDE4 inhibitor 55 carcinoids 55 antiangiogenic therapy 55 ADME properties 55 multicenter randomized controlled 55 colorectal tumor 55 hematopoietic progenitor cells 54 lentiviral 54 NMES 54 intestinal mucosa 54 depsipeptide 54 lymphoid tumors 54 echogenicity 54 Sanvar R 54 cerebellar vermis 54 norepinephrine reuptake inhibition 54 pharmacodynamic profiles 54 adjuvant systemic 54 Chronic lymphocytic leukemia 54 Stabilimax NZ 54 histopathologic examination 54 Glypromate 54 5 HT1A receptor 54 Phase IIb clinical trials 54 Lumbar Interbody Fusion 54 clade B 54 Campath ® 54 serum biomarker 54 Levulan ® PDT 54 abacavir Ziagen 54 Phase IIIb study 54 R roscovitine 54 delipidation 54 rt PA 54 immunohistochemistry IHC 54 anterior pituitary 54 cat dander allergy 54 immunological diseases 54 carcinomatosis 54 PDGF receptor 54 topoisomerase II inhibitor 54 APTIMA HPV 54 cinacalcet 54 Capsule endoscopy 54 PhG alpha 1 54 uPA 54 Granulocyte Colony Stimulating Factor 54 prognostic indicators 54 pharmacokinetic PK 54 Thalomid ® 54 saphenous vein graft 54 Aprotinin 54 relapsed MM 54 intra abdominal abscess 54 mTOR mammalian target 54 blood clot dissolver 54 CONBRIZA 54 HLA DRB1 * 54 computed tomographic 54 transcranial Doppler ultrasound 54 axonal degeneration 54 ureteral stents 54 Platinol ® cisplatin 54 T1 weighted images 54 selective inhibition 54 bronchoalveolar lavage 54 troponin assay 54 hamartomas 54 peptide antigens 54 vivo validation 54 NOD SCID mice 54 Doxil ® 54 clinicopathologic 54 keratoplasty 54 gadolinium enhanced 54 pretargeting 54 nonclinical studies 54 Radiofrequency ablation 54 coagulation abnormalities 54 cardiac allograft vasculopathy 54 delafloxacin 54 coronary stenting 54 nonmetastatic 54 recombinant enzyme 54 pediatric acute lymphoblastic 54 Solorel TM 54 PD LID 54 endoscopic retrograde 54 CanAg 54 neoplastic diseases 54 esophagogastric 54 HepaSphere 54 gefitinib Iressa 54 sd rxRNA 54 epoetin alpha 54 malignant prostate 54 Metastatic colorectal cancer 54 Combidex 54 pharmacokinetic characteristics 54 physico chemical properties 54 biliary stones 54 plasma kallikrein 54 pulmonary infiltrates 54 Prof. Gozes 54 hereditary deficiency 54 resorptive 54 Immunohistochemical staining 54 prostaglandin synthesis 54 Diamondback #deg 54 S#P# receptor 54 hepatocellular carcinomas 54 antitumor immunity 54 radiolabeled TM# 54 AlloMap 54 SYN# 54 valve implantation 54 neurogenic bladder 54 gastric adenocarcinoma 54 prostate cancer CaP 54 cytotoxic effects 54 carotid artery stent 54 intraventricular 54 mGlu2 3 54 ADPKD 54 TNF alpha inhibitor 54 IMiDs R 54 physicochemical properties 54 AT1R 54 nanocarrier 54 Eluting Stent 54 YONDELIS R 54 hematopoietic cancers 54 rhIGF-I/rhIGFBP-3 54 keratinocyte 54 EGS# 54 HCV protease inhibitors 54 murine model 54 basal cell carcinoma BCC 54 StemEx R 54 COPERNICUS 54 Optical coherence tomography 54 Cimzia ® certolizumab pegol 54 breast cancer subtypes 54 skeletal myoblasts 54 tropism testing 54 intracavitary 54 Hexvix ® 54 peritoneal carcinomatosis 54 etiologic 54 patientswith 54 pulmonary artery banding 54 nimodipine 54 ALN TTR# 54 monoclonal 54 metabolomic profiling 54 toxicologic 54 intranasal delivery 54 pharmacologic approaches 54 nodal metastases 54 methylation biomarkers 54 antifibrotic 54 Myelodysplastic syndromes MDS 54 experimental autoimmune encephalomyelitis 54 CEQ# 54 intra arterial 54 Chronic Heart Failure 54 polyarticular 54 Macaca mulatta 54 immunohistochemical 54 enzyme inhibitor 54 polyclonal antibody 54 RQ PCR 54 secondary hyperparathyroidism 54 alefacept 54 Neupogen ® 54 TheraSphere 54 Hepatocytes 54 multicenter prospective 54 HIF 1α 54 dosage regimens 54 preclinical efficacy 54 IgG1 antibody 54 ischemia induced 54 #beta HSD1 54 endovascular aneurysm repair 54 myelofibrosis polycythemia vera 54 CardioWest TAH t 54 GAD# 54 Soliris eculizumab 54 metastatic gastric 54 plasmid DNA vaccine 54 GPI anchored 54 ATIR 54 atherothrombotic 54 vesicoureteral reflux VUR 54 adrenalectomy 54 Onrigin TM 54 scintigraphic 54 miRview mets 54 functional mitral regurgitation 54 adipose derived stem cell 54 peripheral arterial 54 AE# vaccine 54 immunosuppressant therapy 54 physiologically relevant 54 Toraymyxin 54 immunohistochemical analysis 54 Serum HER-2/neu Test 54 DNA intercalator 54 Src inhibitors 54 Gleevec resistant 54 Actimmune ® 54 cypin 54 pharmaceutically relevant 54 factor HGF 53 Nucleic acids 53 bone grafting procedures 53 Azedra 53 genotype phenotype 53 CP CPPS 53 TAXUS TM 53 mammalian fatty acid 53 C1INH 53 myelomas 53 radical cystectomy 53 VGV 1 53 Fludara ® 53 humanised antibody 53 adipokines 53 Methylnaltrexone 53 nephropathic cystinosis 53 immunosuppression therapy 53 inhibitor RG# 53 HuMax TAC 53 Biolimus A9 53 anthracycline chemotherapy 53 Diabetic Neuropathy 53 cytologic 53 HERmark assay 53 Onrigin 53 posttranslational modification 53 interferon γ 53 Vidofludimus 53 Rheos System 53 HuLuc# 53 Hepatic 53 kidney allograft 53 Lymphoid 53 Rosetta Genomics microRNA 53 Orally administered 53 inverse agonist 53 PrevOnco 53 Alfacell proprietary ribonuclease 53 Epi LASIK 53 PORxin TM 53 Nexavar sorafenib 53 atherothrombotic disease 53 investigational therapies 53 Certican 53 CT angiography CTA 53 Surgical excision 53 Surgical resection 53 preoperative diagnosis 53 idiopathic pulmonary arterial hypertension 53 Non inferiority 53 Akt activation 53 radiotherapeutic 53 cisplatin gemcitabine 53 PAOD 53 thalidomide Thalomid 53 SNCA 53 Hemopurifier ® 53 erythropoiesis 53 thyroid carcinoma 53 thrombolytic agent 53 prognostic variables 53 Lixivaptan 53 carcinoembryonic antigen 53 cysteamine bitartrate 53 orally bioavailable mimics 53 BChE 53 non nucleoside 53 hypereosinophilic syndrome 53 prospective multicenter 53 striatal neurons 53 miRview ™ squamous 53 nodal dissection 53 G#DT 53 NICE SUGAR 53 demonstrated antitumor activity 53 plexiform 53 enzymatic pathways 53 oncological outcomes 53 Raptiva R 53 antisense molecules 53 liver metastasis 53 multimodality imaging 53 percutaneous drainage 53 observational cohort study 53 JAK2 enzyme 53 N glycan 53 transthyretin amyloidosis 53 Corus CAD 53 metabolite concentrations 53 antiandrogens 53 novel immunomodulatory 53 immunoblotting 53 cellular immunotherapy 53 cyclic peptide 53 cervical lymph nodes 53 Th2 cytokines 53 Anti Bacterial Envelope 53 glycosylated 53 enzyme kinetics 53 skeletal metastases 53 laterality 53 colorectal liver metastases 53 biodegradable implant 53 Luteinizing Hormone Releasing Hormone 53 Recombinant Human 53 trastuzumab emtansine T DM1 53 demethylating agent 53 Fourier domain 53 Allovectin 7 ® 53 epinastine 53 CTAP# Capsules 53 LEUKINE 53 morphometrics 53 Aldosterone 53 ON #.Na 53 adult mesenchymal stem 53 somatostatin analogues 53 nonischemic 53 acyclovir Lauriad ® 53 gene deletions 53 RhuDex R 53 intra abdominal infections 53 Molecular imaging 53 T2DM 53 mTOR inhibitors 53 diffusion tensor 53 retroviral vectors 53 lipid soluble 53 genomic profiling 53 oncological indications 53 artery embolization 53 Cerashield 53 Intra arterial 53 hippocampal neurons 53 Dr. Fehlings 53 PhotoCure 53 colorectal adenoma 53 Computed tomography 53 paclitaxel poliglumex 53 PHPT 53 kinase inhibition 53 ascending aortic 53 TGF alpha 53 OHR/AVR# 53 soluble proteins 53 clevidipine 53 muscle contractility 53 artery stenosis 53 ImmuKnow R 53 anti angiogenic drugs 53 gauge vitrectomy 53 Lp PLA 2 53 pancreatic ductal 53 thymectomy 53 LPLD 53 TLIF 53 immunochemical fecal occult 53 lentiviral vectors 53 clinically evaluable 53 Sebivo 53 angiographically 53 Angiolix 53 RNAi compounds 53 Hematological 53 histopathologic findings 53 AlloMap testing 53 adipocyte differentiation 53 E#F# 53 Vascular Wrap TM 53 CINtec R 53 cartilage regeneration 53 epoprostenol 53 localized prostate 53 SMARTICLES ® 53 novel peptide 53 CINTREDEKIN BESUDOTOX 53 arterial calcification 53 soluble receptor 53 Polymorphism 53 monophasic 53 pentamidine 53 Immunotherapeutic 53 gastric cardia 53 alpha1 antitrypsin deficiency 53 tumor histology 53 lenalidomide dexamethasone 53 anti miRs 53 pan HDAC inhibitor 53 C# fullerenes 53 Acute Myocardial Infarction AMI 53 PNA FISH TM 53 TKM ApoB 53 Fully Covered Stent 53 allogeneic HSCT 53 Amrubicin 53 Histologically 53 Leydig cell 53 menadione 53 samalizumab 53 pancreatectomy 53 intraoperative ultrasound 53 medically inoperable 53 c myb 53 Tyrosine Kinase Inhibitors 53 RNAi therapeutic targeting 53 Mitomycin C 53 monoclonal gammopathy 53 PEGylated anti 53 postoperative AF 53 CG# [003] 53 allogeneic epidermal 53 Alequel 53 Vaxfectin TM 53 NAVISTAR R 53 activin 53 Evoltra ® 53 thyroid carcinomas 53 eIF 4E 53 myeloproliferative 53 TNM staging 53 compound AEOL # 53 sorafenib Nexavar 53 antiplatelet therapies 53 CC genotype 53 somatostatin receptor 53 Phylogenetic analyzes 53 Papillary 53 Allogeneic 53 cranial irradiation 53 Photodynamic therapy 53 nucleotide variations 53 Azacitidine 53 pegylated 53 prognostic biomarker 53 prostate TURP 53 Ultrasonography 53 neovascularization 53 schwannomas 53 familial amyloidotic polyneuropathy FAP 53 LHRH antagonists 53 Immunohistochemistry 53 papillomatosis 53 coagulopathy 53 CMV reactivation 53 Fibroblast Growth Factor Receptor 53 obstructive lesions 53 DACH platinum 53 recombinant albumin 53 SYNTAX trial 53 magnetic resonance angiography MRA 53 cyclophilin inhibitor 53 allogeneic bone marrow 53 motor neuron degeneration 53 myocyte 53 hybridoma cell 53 Thyroid hormones 53 Microplasmin 53 densitometry 53 Liprotamase 53 bronchoscopic 53 phase III isavuconazole 53 adrenocortical cancer 53 F FDG PET 53 multiprotein complex 53 endobronchial 53 nanoparticle aggregates 53 RezularTM 53 Biphasic 53 β blockers 53 endoluminal 53 membranous nephropathy 53 targeting PCSK9 53 ATPace TM 53 unresectable tumors 53 endocrine therapies 53 peptidic 53 Multivariate analysis 52 Fabry Disease 52 Tomographic 52 Onconase 52 chronic thromboembolic pulmonary 52 phase IIIb 52 #p# [003] 52 FDG PET scans 52 neovascularisation 52 pulmonary metastasis 52 ECTRIMS 52 complexation 52 Ramelteon 52 vessel occlusion 52 autonomic dysfunction 52 bisulfite sequencing 52 coronary stent implantation 52 malignant pleural mesothelioma 52 prostate carcinomas 52 HepaGam B 52 conditional logistic regression 52 anatomic structures 52 microbiologically evaluable 52 CA9 SCAN 52 HuMax Inflam 52 Coronary CTA 52 BCR ABL inhibitor 52 Interferon alpha 52 AAV vector 52 Octreolin 52 Magnetic resonance 52 Kinoid 52 ACOMPLIA R 52 Medidur 52 CaPSURE 52 Val HeFT 52 transfection reagents 52 treating neuropathic pain 52 bypass grafting 52 sunitinib Sutent 52 recombinant antibodies 52 extracranial 52 humanized monoclonal antibodies 52 Androgen deprivation therapy 52 CT perfusion imaging 52 hyperalgesia 52 Umbilical cord stem cells 52 Stenting Trial CREST 52 nutrient supplementation 52 multicenter randomized clinical 52 axonal damage